Alban Ziegler,Carrie Koval-Burt,Denise M Kay,Sharon F Suchy,Amber Begtrup,Katherine G Langley,Rebecca Hernan,Laura M Amendola,Brenna M Boyd,Jennifer Bradley,Tracy Brandt,Lilian L Cohen,Alison J Coffey,Joseph M Devaney,Beata Dygulska,Bethany Friedman,Ramsay L Fuleihan,Awura Gyimah,Sihoun Hahn,Sean Hofherr,Kathleen S Hruska,Zhanzhi Hu,Médéric Jeanne,Guanjun Jin,D Aaron Johnson,Haluk Kavus,Rudolph L Leibel,Steven J Lobritto,Stephen McGee,Joshua D Milner,Kirsty McWalter,Kristin G Monaghan,Jordan S Orange,Nicole Pimentel Soler,Yeyson Quevedo,Samantha Ratner,Kyle Retterer,Ankur Shah,Natasha Shapiro,Robert J Sicko,Eric S Silver,Samuel Strom,Rebecca I Torene,Olatundun Williams,Vincent D Ustach,Julia Wynn,Ryan J Taft,Paul Kruszka,Michele Caggana,Wendy K Chung

Abstract:Importance: The feasibility of implementing genome sequencing as an adjunct to traditional newborn screening (NBS) in newborns of different racial and ethnic groups is not well understood. Objective: To report interim results of acceptability, feasibility, and outcomes of an ongoing genomic NBS study in a diverse population in New York City within the context of the New York State Department of Health Newborn Screening Program. Design, setting, and participants: The Genomic Uniform-screening Against Rare Disease in All Newborns (GUARDIAN) study was a multisite, single-group, prospective, observational investigation of supplemental newborn genome screening with a planned enrollment of 100 000 participants. Parent-reported race and ethnicity were recorded at the time of recruitment. Results of the first 4000 newborns enrolled in 6 New York City hospitals between September 2022 and July 2023 are reported here as part of a prespecified interim analysis. Exposure: Sequencing of 156 early-onset genetic conditions with established interventions selected by the investigators were screened in all participants and 99 neurodevelopmental disorders associated with seizures were optional. Main outcomes and measures: The primary outcome was screen-positive rate. Additional outcomes included enrollment rate and successful completion of sequencing. Results: Over 11 months, 5555 families were approached and 4000 (72.0%) consented to participate. Enrolled participants reflected a diverse group by parent-reported race (American Indian or Alaska Native, 0.5%; Asian, 16.5%; Black, 25.1%; Native Hawaiian or Other Pacific Islander, 0.1%; White, 44.7%; 2 or more races, 13.0%) and ethnicity (Hispanic, 44.0%; not Hispanic, 56.0%). The majority of families consented to screening of both groups of conditions (both groups, 90.6%; disorders with established interventions only, 9.4%). Testing was successfully completed for 99.6% of cases. The screen-positive rate was 3.7%, including treatable conditions that are not currently included in NBS. Conclusions and relevance: These interim findings demonstrate the feasibility of targeted interpretation of a predefined set of genes from genome sequencing in a population of different racial and ethnic groups. DNA sequencing offers an additional method to improve screening for conditions already included in NBS and to add those that cannot be readily screened because there is no biomarker currently detectable in dried blood spots. Additional studies are required to understand if these findings are generalizable to populations of different racial and ethnic groups and whether introduction of sequencing leads to changes in management and improved health outcomes. Trial registration: ClinicalTrials.gov Identifier: NCT05990179.

Feasibility and Acceptability of a Newborn Screening Program Using Targeted Next-Generation Sequencing in One Maternity Hospital in Southern Belgium

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions

Universal newborn screening using genome sequencing: early experience from the GUARDIAN study

Genomic Sequencing As a First-Tier Screening Test and Outcomes of Newborn Screening.

Genome-based newborn screening for severe childhood genetic diseases has high positive predictive value and sensitivity in a NICU pilot trial

Exploring the feasibility, acceptability and impact of genomic newborn screening for rare diseases in England: A study protocol for the Generation Study - Process and Impact Evaluation

Data-driven prioritization of genetic disorders for global genomic newborn screening programs

‘Integrating Ethics and Equity with Economics and Effectiveness for newborn screening in the genomic age: A qualitative study protocol of stakeholder perspectives

Newborn screening with targeted sequencing: a multicenter investigation and a pilot clinical study in China

The Modernisation of Newborn Screening as a Pan-European Challenge – An International Delphi Study

Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation

[A prospective study of genetic screening of 2 060 neonates by high-throughput sequencing]

Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe

Patient preferences in genetic newborn screening for rare diseases: study protocol

A Modular Genetic Approach to Newborn Screening from Spinal Muscular Atrophy to Sickle Cell Disease—Results from Six Years of Genetic Newborn Screening

Prequalification of genome-based newborn screening for severe childhood genetic diseases through federated training based on purifying hyperselection

Exome sequencing in newborns with congenital deafness as a model for genomic newborn screening: the Baby Beyond Hearing project

Accelerated genome sequencing with controlled costs for infants in intensive care units: a feasibility study in a French hospital network

SeqFirst: Building equity access to a precise genetic diagnosis in critically ill newborns